Unicycive Therapeutics, INC 8-K filings

Unicycive Therapeutics reports successful results from its OLC pivotal trial, demonstrating favorable tolerability and safety, paving the way for a New Drug Application submission in Q3 2024.

Unicycive Therapeutics held its annual meeting on June 20, 2024, where stockholders elected four directors, ratified the appointment of its accounting firm, and approved several key proposals.

Unicycive Therapeutics reported its Q1 2024 financial results and provided a business update, highlighting progress on its clinical trials for kidney disease treatments.

Unicycive Therapeutics reported its 2023 financial results, highlighted clinical trial progress for its kidney disease therapies, and secured $50 million in funding.

Unicycive Therapeutics has successfully raised $50 million through a private placement of Series B Convertible Preferred Stock to fund its clinical development programs.

Unicycive Therapeutics has eliminated several series of preferred stock and issued new preferred stock and amended warrants through an exchange agreement with accredited investors.

Unicycive Therapeutics has successfully regained compliance with Nasdaq's minimum market value and bid price requirements, resolving previous listing concerns.